Neximmune

Neximmune EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Neximmune (NEXI) as of Oct 18, 2026 is -63.08 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -53.25 M USD — a change of 18.46% (lower).

EBITDA

-63.08 MUSD

YoY

18.46%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Neximmune is 2022 -63.08 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Neximmune was 2021 -53.25 M USD. It decreases by 18.46% lower compared to the previous year.

The Neximmune EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-13.24 M USD
Jan 1, 2019
-20.89 M USD
Jan 1, 2020
-27.85 M USD
Jan 1, 2021
-53.25 M USD
Jan 1, 2022
-63.08 M USD
The Neximmune EBITDA history
YEAREBITDAYoY
-63.08 MUSD+18.46%
-53.25 MUSD+91.20%
-27.85 MUSD+33.32%
-20.89 MUSD+57.78%
-13.24 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Neximmune Stock analysis

What does Neximmune do? Neximmune Inc, trading under ticker NEXI, is a US-based biotechnology company headquartered in Gaithersburg. Founded in 2021, the company went public on February 12, 2021. It employs 50 people and operates in the Health Care sector. Neximmune focuses on developing immunotherapies using its Artificial Immune Modulation (AIM) platform, which employs nanoparticles to direct T cell responses. The company's product candidates include NEXI-001 for acute myeloid leukemia and NEXI-002 for multiple myeloma. Its AIM technology constructs synthetic dendritic cells to generate targeted immune responses. The company is clinical-stage, developing treatments for oncology and autoimmune disorders. Neximmune is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neximmune stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Neximmune is -63.08 M USD in 2022.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Neximmune changed from -53.25 M USD to -63.08 M USD, representing a 18.46% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Neximmune since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Neximmune historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Neximmune

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Neximmune